**Supplementary Table 1. Clinical and pathological characteristics of SCNEC patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **FIGO 2009 system** | ***P*** | **FIGO 2018 system** | ***P*** |
| **IB1** | **IB2** | **IIA1** | **IIA2** | **IB1** | **IB2** | **IB3** | **IIA1** | **IIA2** | **IIIC1** | **IIIC2** |
| **Age (years，n=64)** |  |  |  |  | 0.698 |  |  |  |  |  |  |  | 0.082 |
| **＜30** | 48.9% | 00.0% | 00.0% | 00.0% |  | 314.3% | 15.3% | 00.0% | 00.0% | 00.0% | 00.0% | 00.0% |  |
| **30-39** | 1328.9% | 330.0% | 120.0% | 250.0% |  | 838.1% | 210.5% | 150.0% | 00.0% | 00.0% | 746.7% | 00.0% |  |
| **40-49** | 1635.6% | 330.0% | 240.0% | 00.0% |  | 523.8% | 1052.6% | 00.0% | 133.3% | 150.0% | 320.0% | 150.0% |  |
| **50-59** | 817.8% | 440.0% | 120.0% | 250.0% |  | 314.3% | 631.6% | 150.0% | 00.0% | 150.0% | 426.7% | 150.0% |  |
| **≥60** | 48.9% | 00.0% | 120.0% | 00.0% |  | 29.5% | 00.0% | 00.0% | 266.7% | 00.0% | 16.7% | 00.0% |  |
| **HPV (n=30)** |  |  |  |  | 0.072 |  |  |  |  |  |  |  | 0.803 |
| **Negative** | 14.5% | 133.3% | 00.0% | 00.0% |  | 00.0% | 00.0% | 00.0% | 133.3% | 116.7% | 00.0% | 00.0% |  |
| **16** | 00.0% | 133.3% | 00.0% | 00.0% |  | 00.0% | 19.1% | 00.0% | 00.0% | 00.0% | 00.0% | 00.0% |  |
| **18** | 1254.5% | 133.3% | 266.7% | 2100.0% |  | 675.0% | 545.5% | 1100.0% | 133.3% | 350.0% | 675.0% | 1100.0% |  |
| **Unclassified** | 940.9% | 00.0% | 133.3% | 00.0% |  | 225.0% | 545.5% | 00.0% | 133.3% | 233.3% | 225.0% | 00.0% |  |
| **Histological homology(n=64)** |  |  |  |  | 0.766 |  |  |  |  |  |  |  | 0.319 |
| **Pure** | 2555.6% | 770.0% | 360.0% | 375.0% |  | 1047.6% | 1368.4% | 2100.0% | 133.3% | 2100.0% | 853.3% | 2100.0% |  |
| **Mixed** | 2044.4% | 330.0% | 240.0% | 125.0% |  | 1152.4% | 631.6% | 00.0% | 266.7% | 00.0% | 746.7% | 00.0% |  |
| **Surgical margins (n=64)** |  |  |  |  | 0.139 |  |  |  |  |  |  |  | 0.001 |
| **Positive** | 12.2% | 110.0% | 120.0% | 125.0% |  | 00.0% | 00.0% | 00.0% | 266.7% | 00.0% | 213.3% | 00.0% |  |
| **Negative** | 4497.8% | 990.0% | 480.0% | 375.0% |  | 21100.0% | 19100.0% | 2100.0% | 133.3% | 2100.0% | 1386.7% | 2100.0% |  |
| **LNM\* (n=64)** |  |  |  |  | 0.023 |  |  |  |  |  |  |  | ＜0.001 |
| **No** | 3782.2% | 550.0% | 480.0% | 125.0% |  | 21100.0% | 19100.0% | 2100.0% | 3100.0% | 2100.0% | 00.0% | 00.0% |  |
| **Yes** | 817.8% | 550.0% | 120.0% | 375.0% |  | 00.0% | 00.0% | 00.0% | 00.0% | 00.0% | 15100.0% | 2100.0% |  |
| **Parametrial (n=64)** |  |  |  |  | ＜0.001 |  |  |  |  |  |  |  | 0.012 |
| **Positive** | 12.2% | 110.0% | 00.0% | 375.0% |  | 00.0% | 00.0% | 00.0% | 00.0% | 00.0% | 426.7% | 150.0% |  |
| **Negative** | 4497.8% | 990.0% | 5100.0% | 125.0% |  | 21100.0% | 19100.0% | 2100.0% | 3100.0% | 2100.0% | 1173.3% | 150.0% |  |
| **LVSI& (n=64)** |  |  |  |  | 0.139 |  |  |  |  |  |  |  | 0.044 |
| **Yes** | 2760.0% | 990.0% | 360.0% | 4100.0% |  | 1047.6% | 1263.2% | 2100.0% | 133.3% | 2100.0% | 1493.3% | 2100.0% |  |
| **No** | 1840.0% | 110.0% | 240.0% | 00.0% |  | 1152.4% | 736.8% | 00.0% | 266.7% | 00.0% | 16.7% | 00.0% |  |
| **Depth invasion(n=63)** |  |  |  |  | 0.072 |  |  |  |  |  |  |  | 0.010 |
| **＜1/3** | 2352.3% | 00.0% | 240.0% | 125.0% |  | 1571.4% | 1052.6% | 00.0% | 133.3% | 00.0% | 00.0% | 00.0% |  |
| **1/3-2/3** | 24.5% | 00.0% | 00.0% | 00.0% |  | 14.8% | 15.3% | 00.0% | 00.0% | 00.0% | 00.0% | 00.0% |  |
| **＞2/3** | 1943.2% | 10100.0% | 360.0% | 375.0% |  | 523.8% | 842.1% | 2100.0% | 266.7% | 2100.0% | 14100.0% | 2100.0% |  |
| **Tumor size（cm,n=64）** |  |  |  |  | ＜0.001 |  |  |  |  |  |  |  | ＜0.001 |
| **≤2** | 2555.6% | 00.0% | 360.0% | 125.0% |  | 21100.0% | 00.0% | 00.0% | 3100.0% | 00.0% | 320.0% | 2100.0% |  |
| **＞2，≤4** | 1942.2% | 220.0% | 120.0% | 250.0% |  | 00.0% | 19100.0% | 00.0% | 00.0% | 00.0% | 533.3% | 00.0% |  |
| **＞4** | 12.2% | 880.0% | 120.0% | 125.0% |  | 00.0% | 00.0% | 2100.0% | 00.0% | 2100.0% | 746.7% | 00.0% |  |
| **Lower uterine involvement (n=64)** |  |  |  |  | 0.014 |  |  |  |  |  |  |  | 0.089 |
| **Positive** | 48.9% | 440.0% | 00.0% | 250.0% |  | 00.0% | 421.1% | 00.0% | 00.0% | 00.0% | 533.3% | 150.0% |  |
| **Negative** | 4191.1% | 660.0% | 5100.0% | 250.0% |  | 21100.0% | 1578.9% | 2100.0% | 3100.0% | 2100.0% | 1066.7% | 150.0% |  |
| **Adjuvant therapy# (n=64)** |  |  |  |  | 0.859 |  |  |  |  |  |  |  | 0.809 |
| **Chemotherapy only** | 614.6% | 110.0% | 00.0% | 133.3% |  | 526.3% | 15.9% | 00.0% | 00.0% | 00.0% | 215.4% | 00.0% |  |
| **Chemoradiotherapy** | 3380.5% | 880.0% | 4100.0% | 266.7% |  | 1263.2% | 1588.2% | 2100.0% | 3100.0% | 2100.0% | 1184.6% | 2100.0% |  |
| **none** | 24.9% | 110.0% | 00.0% | 00.0% |  | 210.5% | 15.9% | 00.0% | 00.0% | 00.0% | 00.0% | 00.0% |  |
| **Involvement of vagina (n=62)** |  |  |  |  | 0.225 |  |  |  |  |  |  |  | ＜0.001 |
| **Yes** | 49.3% | 110.0% | 240.0% | 125.0% |  | 00.0% | 00.0% | 00.0% | 3100.0% | 150.0% | 426.7% | 00.0% |  |
| **No** | 3990.7% | 990.0% | 360.0% | 375.0% |  | 19100.0% | 19100.0% | 2100.0% | 00.0% | 150.0% | 1173.3% | 2100.0% |  |

\*LNM, lymph node metastasis, including pelvic and para-aortic metastasis (among them, four cases underwent para-aortic lymphadenectomy and 2/4 cases were positive); LVSI, lymph-vascular space invasion

# Postoperative adjuvant therapy: none of the patients who received adjuvant therapy chose only radiotherapy